Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirexatamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sirexatamab overview
Leap Therapeutics overview
Leap Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. FL-301, a monoclonal antibody that targets Claudin18.2, is being tested in patients with gastric and pancreatic cancer. The company has an agreement with BeiGene Ltd for development rights and commercialization of DKN-01 in Australia, Asia (excluding Japan) and New Zealand. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Sirexatamab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.